Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 5/20 | 0.56 |
| ▸ | CDC25B | P30305 | 5/20 | 0.56 |
| ▸ | MAP2K7 | O14733 | 4/20 | 0.56 |
| ▸ | S100A4 | P26447 | 1/20 | 0.56 |
| ▸ | BACE1 | P56817 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | NSD2 | O96028 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | TDP2 | O95551 | 1/20 | 0.44 |
| ▸ | G6PD | P11413 | 1/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.44 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21878874 | 0.90 | CDC25A (0.54) | CDC25ACDC25BMAP2K7S100A4BACE1 | |
| SCHEMBL30692083 | 0.90 | CDC25A (0.54) | CDC25ACDC25BMAP2K7S100A4BACE1 | |
| SCHEMBL28109252 | 0.87 | MAPT (0.51) | CDC25ACDC25BMAP2K7S100A4PTPN1 | |
| SCHEMBL11268928 | 0.85 | HDAC6 (0.48) | CDC25ACDC25BMAP2K7S100A4BACE1 | |
| SCHEMBL5810776 | 0.83 | PARK7 (0.58) | CDC25ACDC25BS100A4BACE1PTPN1 | |
| SCHEMBL8615961 | 0.82 | CDC25B (0.54) | CDC25ACDC25BMAP2K7S100A4BACE1 | |
| SCHEMBL6535682 | 0.81 | CYP19A1 (0.53) | CDC25ACDC25BMAP2K7S100A4PTPN1 | |
| SCHEMBL128020 | 0.80 | S100A4 (0.53) | CDC25ACDC25BMAP2K7S100A4BACE1 | |
| SCHEMBL30673380 | 0.80 | S100A4 (0.53) | CDC25ACDC25BMAP2K7S100A4BACE1 | |
| SCHEMBL28808062 | 0.80 | PKM (0.48) | CDC25ACDC25BMAP2K7S100A4PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099917-A1 | REVERSIBLY REDUCIBLE MATERIALS AND USE THEREOF | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2018-04-12 | — | — | US | disclosed |
| US-20150192852-A1 | LITHOGRAPHIC PRINTING PLATE PRECURSOR AND PLATE MAKING METHOD | FUJIFILM CORPORATION (JP) | 2015-07-09 | — | — | US | disclosed |
| US-20090247472-A1 | TYPE 1, 4-NAPHTOQUINONE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USE OF THESE COMPOUNDS AS ANTI-CANCER AGENTS | FLUOFARMA (FR) | 2009-10-01 | — | — | US | disclosed |
| US-20090247472-A1 | TYPE 1, 4-NAPHTOQUINONE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USE OF THESE COMPOUNDS AS ANTI-CANCER AGENTS | FLUOFARMA (FR) | 2009-10-01 | — | — | US | disclosed |
| WO-2007125196-A1 | TYPE 1, 4-NAPHTOQUINONE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USE OF THESE COMPOUNDS AS ANTI-CANCER AGENTS | FLUOFARMA (FR) | 2007-11-08 | — | — | WO | disclosed |
| EP-1015422-A4 | HIV MATRIX PROTEIN TYROSINE POSITION 29 POCKET BINDERS | PICOWER INST MED RES (US) | 2004-12-08 | — | — | EP | disclosed |
| EP-1015422-A1 | HIV MATRIX PROTEIN TYROSINE POSITION 29 POCKET BINDERS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999009005-A1 | HIV MATRIX PROTEIN TYROSINE POSITION 29 POCKET BINDERS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1999-02-25 | — | — | WO | disclosed |
| US-5849793-A | HIV matrix protein tyrosine position 29 pocket binders | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099917-A1 | REVERSIBLY REDUCIBLE MATERIALS AND USE THEREOF | NES, CBR3, SQOR | CDC25A 589/4885CDC25B 809/4885MAP2K7 4586/4885 |
| US-20090247472-A1 | TYPE 1, 4-NAPHTOQUINONE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USE OF THESE COMPOUNDS AS ANTI-CANCER AGENTS | CCNA1, MKI67, CCNT1 | CDC25A 14/4885CDC25B 90/4885MAP2K7 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.